若年性黄斑変性症(シュタルガルト病)の治療薬パイプライン動向(2015年上半期版)...市場調査レポートについてご紹介

【英文タイトル】Juvenile Macular Degeneration (Stargardt Disease) - Pipeline Review, H1 2015

▼当市場調査レポートの詳細内容確認、お問い合わせ及びご購入申込は下記ページでお願いします。▼マーケットレポート

【レポートの概要(一部)】

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Juvenile Macular Degeneration (Stargardt Disease) Overview 6
Therapeutics Development 7
Pipeline Products for Juvenile Macular Degeneration (Stargardt Disease) – Overview 7
Pipeline Products for Juvenile Macular Degeneration (Stargardt Disease) – Comparative Analysis 8
Juvenile Macular Degeneration (Stargardt Disease) – Therapeutics under Development by Companies 9
Juvenile Macular Degeneration (Stargardt Disease) – Therapeutics under Investigation by Universities/Institutes 10
Juvenile Macular Degeneration (Stargardt Disease) – Pipeline Products Glance 11
Clinical Stage Products 11
Early Stage Products 12
Juvenile Macular Degeneration (Stargardt Disease) – Products under Development by Companies 13
Juvenile Macular Degeneration (Stargardt Disease) – Products under Investigation by Universities/Institutes 14
Juvenile Macular Degeneration (Stargardt Disease) – Companies Involved in Therapeutics Development 15
Acucela Inc. 15
Alkeus Pharmaceuticals, Inc. 16
Ocata Therapeutics, Inc. 17
Sanofi 18
Juvenile Macular Degeneration (Stargardt Disease) – Therapeutics Assessment 19
Assessment by Monotherapy Products 19
Assessment by Target 20
Assessment by Mechanism of Action 22
Assessment by Route of Administration 24
Assessment by Molecule Type 26
Drug Profiles 28
ALK-001 – Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
echothiophate iodide – Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
emixustat hydrochloride – Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
Gene Therapy for Stargardt Disease – Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
MA09-hRPE – Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
Small Molecule for Stargardt Disease – Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
StarGen – Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
VSM-20R – Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
Juvenile Macular Degeneration (Stargardt Disease) – Recent Pipeline Updates 40
Juvenile Macular Degeneration (Stargardt Disease) – Product Development Milestones 51
Featured News & Press Releases 51
Oct 15, 2014: ACT Announces Positive Results from Two Clinical Trials Published in The Lancet Using Differentiated Stem Cell-Derived Retinal Pigment Epithelium (RPE) Cells for the Treatment of Macular Degeneration 51
Sep 25, 2014: Advanced Cell Technology Announces Final Patient Treated in Stargardt’s Macular Degeneration Phase 1 Trial in the United Kingdom 52
Jul 17, 2013: ACT Secures Approval from Data Safety Monitoring Board to Complete Third Patient Cohort in All Three Clinical Trials 52
May 16, 2013: ACT Confirms Clinical Trial Participant Shows Improvement In Vision Following Treatment With Human Embryonic Stem Cells 53
Apr 23, 2013: ACT Initiates Higher-Dosage Patient Treatment In European Phase I Study For Macular Degeneration 53
Apr 15, 2013: ACT Treats First Patient With Better Vision In Clinical Trial For Stargardt’s Macular Dystrophy 54
Apr 01, 2013: ACT Initiates Treatment Of Higher-dosage Cohort In Clinical Trials For Dry Age-related Macular Degeneration And Stargardt’s Macular Dystrophy 54
Mar 14, 2013: Advanced Cell Technology Receives DSMB Approval To Initiate Treatment Of Third Patient Cohort In All Three Clinical Trials Using hESC-derived RPE Cells 55
Jan 08, 2013: Advanced Cell Technology Achieves Clinical Milestone 56
Dec 17, 2012: ACT Completes Higher-Dosage Cohort In European Clinical Trial For Stargardt’s Macular Dystrophy Using Retinal Pigment Epithelial Cells 57
Appendix 58
Methodology 58
Coverage 58
Secondary Research 58
Primary Research 58
Expert Panel Validation 58
Contact Us 59
Disclaimer 59


【レポート販売概要】

■ タイトル:若年性黄斑変性症(シュタルガルト病)の治療薬パイプライン動向(2015年上半期版)
■ 英文:Juvenile Macular Degeneration (Stargardt Disease) - Pipeline Review, H1 2015
■ 発行日:2015年1月22日
■ 調査会社:Global Markets Direct
■ 商品コード:GMDHC6089IDB
■ 調査対象地域:グローバル
※当サイトは世界の市場調査レポート紹介サイトです。市場規模、市場動向、市場予測など、多様な分析データを含むグローバル調査レポートをご案内致します。日本国内を含むアジア太平洋、中国、ヨーロッパ、アメリカ、北米、中南米、中東、アフリカ地域などにおける、製品、サービス、技術、企業(メーカー、ベンダー)、市場シェア、市場環境など多様な項目に対応致します。当サイトでご紹介するレポートは「市場調査レポート販売サイトのMarketReport.jp」でお問い合わせ及びご購入可能です。